Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 1, 1996, Pages 149-159

  Cohn, Jeffrey S ^a   Tremblay, Michel ^b   Amiot, Mireille ^b   Bouthillier, Daniel ^b   Roy, Madeleine ^b   Genest Jr , Jacques ^a   Davignon, Jean ^b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b NONE

Author keywords

apoE phenotype; atherosclerosis; coronary artery disease; FPLC; triglyceride rich lipoproteins

Indexed keywords

APOLIPOPROTEIN E; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; INCIDENCE; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL;

EID: 0030060845     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.1.149     Document Type: Article

References (54)

1. Mahley RW. Atherogenic hyperlipoproteinemia: the cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin North Am. 1982;66:375-402.
2. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill Publishing Co: 1989:1195-1213.
3. van Vlijmen BJM, van den Maagdenberg AMJM. Gijbels MJJ, van der Boom H, HogenEsch H, Frants RR, Hofker MH, Havekes LM. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest. 1994;93: 1403-1410.
4. Fazio S, Sanan DA, Lee Y-L, Ji Z-S, Mahley RW, Rail SC Jr. Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E (Arg112,Cys142). Arterioscler Thromb. 1994;14:1873-1879.
5. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholester-olaemic men. Lancet. 1987;8550:62-66.
6. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
7. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83-97.
8. Zhang SH, Reddick RL, Pierdrahita JA, Maeda N. Spontaneous hypereholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
9. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
10. Gibson JC, Rubinstein A, Bukberg PR, Brown WV. Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects. J Lipid Res. 1983;24:886-898.
11. Gibson JC, Goldberg RB, Rubinstein A, Ginsberg HN, Brown WV, Baker S, Joffe BI, Seftel HC. Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia. Arteriosclerosis. 1987;7:401-407.
12. Rubinstein A, Gibson JC, Paterniti JR Jr, Kakis G, Little A, Ginsberg HN, Brown WV. Effect of heparin-induced lipolysis on the distribution of apolipoprotein E among lipoprotein subclasses: studies with patients deficient in hepatie triglyceride lipase and lipoprotein lipase. J Clin Invest. 1985;75:710-721.
13. Gibson JC, Rubinstein A, Brown WV, Ginsberg HN, Greten H, Norum R, Kayden H. ApoE-containing lipoproteins in low or high density lipoprotein deficiency. Arteriosclerosis. 1985;5:371-380.
14. Fredrickson DS, Goldstein JL, Brown MS. The familial hyperlipoproteinemias. In: Stanbury MF, Wyngaarden JB, Fredrickson DS, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill Publishing Co; 1978:604-655.
15. The Lipid Research Clinics. Population Studies Data Book, Vol I: The Prevalence Study. Washington, DC: US Dept of Health and Human Services; 1980. Publication NIH 80-1527.
16. März W, Siekmeier R, Scharnagl H, Seiffert UB, Gross W. Fast lipoprotein chromatography: a new method of analysis for plasma lipoproteins. Clin Chem. 1993;39:2276-2281.
17. Tallis GA, Shephard MDS, Whiting MJ. Lipoprotein profiling by high performance gel chromatography. Clin Chim Acta. 1994;228: 171-179.
18. Bury J, Vercaemst R, Rosseneu M, Belpaire F. Apolipoprotein E quantified by enzyme-linked immunosorbent assay. Clin Chem. 1986;32:265-270.
19. Lipid Research Clinics Program. Manual of Laboratory Operations, Volume I. Washington, DC: US Government Printing Office; 1974.
20. Bouthilier D, Sing CF, Davignon J. Apolipoprotein E phenotyping with a single gel method: application to the study of informative matings. J Lipid Res. 1983;24:1060-1069.
21. Hill JS, Pritchard PH. Improved phenotyping of apolipoprotein E: application to population frequency distribution. Clin Chem. 1990; 36:1871-1874.
22. Neter J, Wasserman W, Kutner MH. Applied Linear Statistical Models. 3rd ed. Boston, Mass: Irwin, Richard D., Inc; 1990:349-385.
23. Utermann G. Genetic polymorphism of apolipoprotein E: impact on plasma lipoprotein metabolism. In: Crepaldi G, Tiengo A, Baggio G, eds. Diabetes, Obesity, and Hyperlipidemias III. Amsterdam, Netherlands: Elsevier Science Publishing Co; 1985:1.
24. Smit M, de Knijff P, Rosseneu M, Bury J. Klasen E, Frants R, Havekes L. Apolipoprotein E polymorphism in the Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum Genet. 1988;80:287-292.
25. Gracia V, Fiol C, Hurtado I, Pintó X, Argimon JM, Castiñeiras MJ. An enzyme-linked immunosorbent assay method to measure human apolipoprotein E levels using commercially available reagents: effect of apolipoprotein E polymorphism on serum apolipoprotein E concentration. Anal Biochem. 1994;223:212-217.
26. Pagnan A, Havel RJ, Kane JP, Kotite L. Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia. J Lipid Res. 1977;18:613-622.
27. Manzato E, Pagnan A, Ziron L, Gasparotto A, Braggion M. Double pre-beta lipoprotein: isolation and characterization of the two populations of very low density lipoproteins by zonal ultraeentrifugation. Arteriosclerosis. 1984;4:598-603.
28. Bard J-M, Delattre-Lestavel S, Clavey V, Pont P, Derudas B, Parra H-J, Fruchart J-C. Isolation and characterization of two sub-species of Lp(a), one containing apoE and one free of apoE. Biochim Biophys Acta. 1992;1127:124-130
29. Von Eckardstein A, Huang Y, Wu S, Funke H, Noseda G, Assmann G. Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency. Anerioscler Thromb Vase Biol. 1995;5:691-703.
30. Hegele RA, Little JA, Vezina C, Maguire GF, Tu L, Wolever TS, Jenkins DJA, Connelly PW. Hepatic lipase deficiency: clinical, biochemical and molecular genetic characteristics. Anerioscler Thromb. 1993;13:720-728.
31. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA. Brewer HB Jr. Familial apolipoprotein E deficiency. J Clin Invest. 1986;8:1206-1219.
32. Fredrickson DS, Morganroth J, Levy RI. Type III hyperlipoproteinemia: an analysis of two contemporary definitions. Ann Intern Med. 1975;2:150-157.
33. Blum CB, Aron L, Sciacca R. Radioimmunoassay studies of human apolipoprotein E. J Clin Invest. 1980;66:1240-1250.
34. Havel RJ, KotiteL, Vigne J-L, Kane JP, Tun P,Phillips N, Chen GC. Radioimmunoassay of human arginine-rich apolipoprotein, apoproten E. J Clin Invest. 1980;66:1351-1362.
35. Wilson HM, Patel JC, Russell D, Skinner ER. Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma high density lipoprotein in coronary heart disease. Clin Chim Acta. 1993;220:175-187.
36. Curry MD, McConathy WJ, Alaupovic P, Ledford JH, Popovic M. Determination of human apolipoprotein E by electroimmunoassay. Biochim Biophys Acta. 1976;439:413-425.
37. Kushwaha RS, Hazzard WR, Wahl PW, Hoover JJ. Type III hyperlipoproteinemia: diagnosis in whole plasma by apolipoprotein-E immunoassay. Ann Intern Med. 1977;87:509-516.
38. Falko JM, Schonfeld G, Witztum JL, Kolar JB, Weidman SW, Steelman R. Effects of diet on apolipoprotein E levels and on the apoprotein E subspecies in human plasma lipoproteins. J Clin Endocrinol Metab. 1980;50:521-528.
39. Milne RW, Doust-Blazy PH, Marcel YL, Retegui L. Characterization of monoclonal antibodies against human apolipoprotein E. J Clin Invest. 1981;68:111-117.
40. Phillips NR, Havel RJ, Kane JP. Sex-related differences in the concentration of apolipoprotein E in human blood plasma and plasma lipoproteins. J Lipid Res. 1983;24:1525-1531.
41. Castro GR, Fielding CJ. Evidence for the distribution of apolipoprotein E between lipoprolein classes in human normocholester-olemic plasma and for the origin of unassociatcd apolipoprotein E (Lp-E). J Lipid Res. 1984;25:58-67.
42. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. In: Born GVR, Schwartz CJ, eds. New Horizons in Coronary Heart Disease. London, England: Science Press Inc; 1993:5.1-5.21.
43. Steinmetz A, Jakobs C, Motzny S, Kaffarnik H. Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins. Arteriosclerosis. 1989;9:40-411.
44. Weisgrabe KH. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. J Lipid Res. 1990;31:1503-1511.
45. Weisgraber KH, Mahley RW. Apoprotein (E-AII) complex of human plasma lipoproteins, I: characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction. J Biol Chem. 1978;253:6281-6288.
46. Manninen V, Tenkanen L, Koskinen P, Huttimen JK, Manntari M, Heinonen OP, Frick MH. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation. 1992;85: 37-45.
47. Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol. 1994;5:395-403.
48. Goldstein JL, Schrott HG, Hazzard WR, Berman EL, Motulsky AG. Hyperlipidemia in coronary artery disease, II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52: 1544-1568.
49. Kaplan NM. The deadly quartet: upper body obesity, glucose intolerance, hypertrielyceridemia and hypertension. Arch Intern Med. 1989;149:1514-1520.
50. Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
51. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta. 1993;223:53-71.
52. Innerarity TL, Arnold KS, Weisgraber KH, Mahley RW. ApoE is the determinant that mediates the receptor uptake of β-very low density lipoproteins by mouse macrophages. Arteriosclerosis. 1986;6: 114-122.
53. Evans AJ, Sawyez CG, Wolfe BM, Connelly PW, Maguire GF, Huff MW. Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by very low density subfractions occurs by different mechanisms. J Lipid Res. 1993;34:703-717.
54. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb. 1994;14:1767-1774.